BCS Private Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
BCS Private Wealth Management's XBI Position: Q1 2026 in Review
BCS Private Wealth Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.1% in Q1 2026, buying an estimated $50.7K and bringing the position to 37,234 shares worth $4.76M. The position accounts for 1.45% of the portfolio, ranked #17.
BCS Private Wealth Management first reported a position in XBI in Q2 2025 and has held it in 4 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- BCS Private Wealth Management held 37,234 shares of State Street SPDR S&P Biotech ETF worth $4.76M as of Q1 2026.
- BCS Private Wealth Management bought 406 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $50.7K.
- State Street SPDR S&P Biotech ETF made up 1.45% of BCS Private Wealth Management's portfolio in Q1 2026, its #17 holding.
- BCS Private Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2025 and has held it in 4 quarters since.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on BCS Private Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.